health
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with ...

First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United StatesEgetis launches Egetis RareLink™, the EMCITATE patient support program, in partnership with PANTHERx® RareFDA granted Egetis a Rare…
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories

Moody? Aggressive? You could have ‘irritable male syndrome’
New York Post

Ozempic and Wegovy linked to brain health risks from caloric cuts
Fox News

After 20 Miscarriages, Mom Celebrates Son’s First Birthday: ‘I Couldn’t Give Up’ (Exclusive)
Yahoo

5 Georgia siblings diagnosed with measles
WSB-TV

People Who Drink Their Own Pee Are Obsessed With AI, Using It to Reassure Themselves That It's a Miraculous Cure-All
Futurism